Scinai Immunotherapeutics Regains Nasdaq Listing Compliance
Ticker: SCNI · Form: 6-K · Filed: Aug 29, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $2.5 m |
| Sentiment | bullish |
Sentiment: bullish
Topics: compliance, listing, nasdaq
Related Tickers: SCNI
TL;DR
Scinai's back on Nasdaq, dodged delisting!
AI Summary
Scinai Immunotherapeutics Ltd. announced on August 29, 2024, that it has regained compliance with the Nasdaq Stock Market's listing requirements. This follows a period where the company was at risk of delisting, but has now met the necessary criteria to remain listed on the Nasdaq.
Why It Matters
Regaining Nasdaq compliance is crucial for Scinai as it ensures continued trading on a major stock exchange, maintaining investor confidence and access to capital markets.
Risk Assessment
Risk Level: low — The company has officially regained compliance with Nasdaq listing rules, removing the immediate risk of delisting.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- Nasdaq Stock Market (company) — Stock exchange where Scinai is listed
- August 29, 2024 (date) — Date of announcement
FAQ
What specific Nasdaq listing rule did Scinai Immunotherapeutics regain compliance with?
The filing states that Scinai received formal notification from the Listing Qualification Department of the Nasdaq Stock Market that the Company has regained compliance with Nasdaq listing requirements, but does not specify which particular rule was at issue.
When was the announcement made regarding Nasdaq compliance?
The announcement was made on August 29, 2024.
What was the previous status of Scinai's listing on the Nasdaq?
Scinai Immunotherapeutics Ltd. had received notification that it was at risk of delisting from the Nasdaq Stock Market, but has now regained compliance.
What is the principal executive office address for Scinai Immunotherapeutics Ltd.?
The principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Does Scinai Immunotherapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Scinai Immunotherapeutics Ltd. files annual reports under Form 20-F.
Filing Stats: 296 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-29 06:29:12
Key Financial Figures
- $2.5 m — intain stockholders' equity of at least $2.5 million, and that it was now back in full
Filing Documents
- ea0212795-6k_scinai.htm (6-K) — 11KB
- ea021279501ex99-1_scinai.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-073532.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 29, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2